Archives
-
pH-Responsive i-Motif ASO Prodrugs for MYCN Silencing
2026-09-20
The reference study developed hairpin antisense oligonucleotide prodrugs that use an i-motif as an acid-responsive structural switch for controlled release. Systematic changes in loop architecture and stem length identified R3-5 and R5-5 as promising constructs for MYCN silencing and apoptosis induction in MYCN-amplified SK-BE(2) cells.
-
Arachidonic Acid Accelerates Vaccine Humoral Immunity
2026-09-19
A 2025 EMBO Molecular Medicine study shows that dietary arachidonic acid can accelerate rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. The work connects lymph-node arachidonic acid metabolism, prostaglandin I2 signaling, and B-cell activation, providing a mechanistic framework for dietary support of germinal-center responses while leaving important questions about dose, safety, and broader vaccine applicability.
-
GLP-1 (9-36) amide: Assay Workflow Guide
2026-09-18
GLP-1 (9-36) amide gives researchers an acute pharmacological way to test whether cAMP and metabolic phenotypes depend on human GLP-1 receptor activity. This guide combines careful peptide handling, concentration–time mapping, receptor controls, and the ligand-crosstalk lessons of high-throughput FRET assays.
-
Benzyl-activated Streptavidin Magnetic Beads: Workflows
2026-09-18
Benzyl-activated Streptavidin Magnetic Beads support rapid, low-background capture of biotinylated proteins, nucleic acids, antibodies, and other targets from complex samples. This guide connects practical magnetic separation workflows with annexin-V research, showing how to optimize capture, troubleshoot recovery, and avoid overinterpreting bead-based results.
-
AR Heterogeneity and Enzalutamide Response in CRPC
2026-09-17
Li and colleagues show that androgen receptor heterogeneity is a functional determinant of castration and enzalutamide response in advanced prostate cancer. Their pathology, genome-editing, xenograft, transcriptomic, and combination-treatment experiments distinguish AR-positive and AR-low or negative disease states and identify BCL-2 as a potential therapeutic vulnerability.
-
Aconitase Activity Colorimetric Assay Kit Guide
2026-09-17
The Aconitase Activity Colorimetric Assay Kit K2226 provides a rapid colorimetric readout of aconitase activity through citrate to isocitrate conversion and detection at 450 nm. It supports TCA cycle enzyme assay workflows and oxidative damage measurement, but it does not independently establish enzyme localization, protein abundance, or the CD28-ARS2-PKM splicing mechanism.
-
DiscoveryProbe FDA-approved Drug Library Workflow
2026-09-16
Build a mechanism-informed screening campaign with 2,320 pre-dissolved clinical compounds, from lipid-dependent cancer phenotypes to orthogonal pathway validation. This workflow adapts a published SREBP screening strategy for drug repositioning screening, pharmacological target identification, and scalable cancer research drug screening.
-
Dual Luciferase Reporter Gene System: Causal Tests
2026-09-16
Discover how the Dual Luciferase Reporter Gene System can connect enhancer activity with endogenous gene expression and cancer-cell phenotypes. This practical guide uses the ZNF263–ULK1 study to explain assay design, normalization, controls, and interpretation beyond a simple reporter readout.
-
Nitrocefin Workflows for β-Lactamase Research
2026-09-15
Nitrocefin converts β-lactamase activity into a rapid yellow-to-red signal, enabling practical screening from purified enzymes, lysates, and microbial samples. This guide connects assay setup, inhibitor testing, resistance profiling, and troubleshooting to recent mechanistic work on the GOB-38 metallo-β-lactamase.
-
HyperScript RT SuperMix for qPCR: Testis RNA Workflow
2026-09-15
Translate RNA-seq findings on histone hyperacetylation and spermatogenesis into a practical, two-step qRT-PCR validation workflow. HyperScript RT SuperMix for qPCR combines a thermally stable reverse transcriptase with mixed priming to support low-abundance, structurally challenging testis RNA while reducing setup complexity.
-
ALC-0315: From Lipid Choice to LNP Translation
2026-09-14
ALC-0315 is more than an ionizable amino lipid selection; its translational value depends on how formulation flow shapes LNP structure, intracellular mRNA transport, and biological performance. Drawing on a 2026 Nature Communications study, this article presents a process-aware framework for using ALC-0315 in reproducible nucleic acid drug delivery research.
-
Tioconazole Workflows for Antifungal Research
2026-09-14
Build reproducible Tioconazole assays with solvent-controlled dosing, concentration-response testing, and mechanism-aware readouts. This guide connects practical antifungal workflows with energy-state and DNA-repair insights while clearly separating established evidence from exploratory cross-domain hypotheses.
-
Dihydroartemisinin: Assays for mTOR and Malaria
2026-09-13
Build more reproducible Dihydroartemisinin experiments with controlled solvent handling, light protection, pathway-focused readouts, and parasite assay designs informed by resistant-strain and washout studies. The workflow distinguishes evidence for the compound itself from assay strategies adapted from related antiplasmodial research.
-
Tioconazole Workflows for Antifungal Research
2026-09-12
Build reproducible Tioconazole experiments around sterol-pathway biology, solvent-matched controls, and orthogonal fungal readouts. The workflow supports antifungal drug development, resistance profiling, and staged fungal infection model optimization without confusing research evidence with clinical guidance.
-
CENPI Drives Breast Cancer via Wnt/β-Catenin
2026-09-11
A 2025 study identifies centromere protein I (CENPI) as an oncogenic driver of breast cancer and connects its activity to Wnt/β-catenin signaling. By integrating patient datasets, cellular assays, xenografts, RNA sequencing, and pathway reporters, the work provides a mechanistic basis for considering CENPI as a biomarker and potential therapeutic target.